Jupiter Neurosciences, Inc. Stock

JUNS

US48208B3024

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-04 EDT			5-day change	1st Jan Change
3.280 ^USD	+0.61%		-21.53%	-95.71%

08-25	Top Premarket Decliners	MT
08-21	US Equity Indexes Rise Despite Surging Bond Yields as US Nears Tariff Deal With Canada	MT

Valuation : Jupiter Neurosciences, Inc.

Market Cap	2.53M 2.18M 2.05M 1.87M 3.49M 239M 3.51M 24.15M 9.37M 122M 9.48M 9.28M 395M	P/E 2024	-126x	P/E 2025	-4.08x
Enterprise Value	4.06M 3.49M 3.29M 3M 5.61M 383M 5.63M 38.77M 15.05M 196M 15.23M 14.9M 634M	EV / Sales 2024	-	EV / Sales 2025	1,681x
Free-Float	78.48%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Jupiter Neurosciences, Inc.

NasdaqUSD

Markets		Quality
Nasdaq	JUNS	Delayed
CBOE	JUNS	Real-time

Dynamic Chart

Latest news : Jupiter Neurosciences, Inc.

08-25	Top Premarket Decliners	MT
08-21	US Equity Indexes Rise Despite Surging Bond Yields as US Nears Tariff Deal With Canada	MT
08-21	US Equity Indexes Rise Despite Surging Bond Yields	MT
08-21	Jupiter Neurosciences Prices $2.0 Million Direct Offering	MT
08-14	Jupiter Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-21	Jupiter Neurosciences Obtains Exclusive US Rights to Potential Psychedelic Therapy for Up to $100 Million	MT
06-30	Jupiter Neurosciences, Inc. Appoints Tomas J. Philipson as Member of Board and Audit Committee and Compensation Committee, Effective June 26, 2026	CI
06-29	Top Premarket Decliners	MT
06-22	Jupiter Neurosciences, Inc. Announces Allison W. Brady Decides to Resign from Board, Audit Committee and Compensation Committee, Effective June 17, 2026	CI
05-27	Jupiter Neurosciences, Inc. Announces Patient Enrollment Underway in Phase 2A Reset Trial in Parkinson's Disease	CI
05-27	Jupiter Neurosciences says patient enrollment underway in phase 2a reset trial in Parkinson's disease	RE
05-14	Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-07	Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia Advisory Board	CI

More news

Analysts' recommendations : Jupiter Neurosciences, Inc.

25-10-27

Jupiter Neurosciences Signs Up to $20 Million Financing Deals With Yorkville Advisors Global

More recommendations

Press Releases : Jupiter Neurosciences, Inc.

08-21	Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering	AQ
08-05	Jupiter Neurosciences, Inc. Announces Reverse Stock Split	AQ
07-22	Jupiter Neurosciences Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million	AQ
07-21	Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million	AQ
07-07	Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson	AQ

More press releases

Managers and Directors : Jupiter Neurosciences, Inc.

Manager	Title	Age	Since
Alexander Rosén ADM	Chief Administrative Officer	34	2015-12-31
Marshall Hayward CTO	Chief Tech/Sci/R&D Officer	71	2015-12-31
Christer Rosén CEO	Chief Executive Officer	74	2015-12-31

Director	Title	Age	Since
Christer Rosén CHM	Chairman	74	2015-12-31
Marshall Hayward BRD	Director/Board Member	71	2015-12-31
Alison Silva BRD	Director/Board Member	48	2017-12-31

More insiders

Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL - a proprietary, enhanced-bioavailability resveratrol formulation - is in a Phase IIa clinical trial for Parkinson's disease. The JOTROL delivery platform allows resveratrol to be consumed in an easily consumable, oral softgel in a patented micellar form. Delivered via the JOTROL platform, resveratrol infuses blood plasma and the central nervous system, and crosses the blood brain barrier, unlocking the compound's potential as a therapeutic for neurodegenerative and neurological diseases, without the GI issues. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a softgel capsule. The Company also commercializes Nugevia, a consumer longevity supplement. It also has rights in ALA-002.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-04	US$3.280	+0.61%	25,001
26-09-03	US$3.260	-4.96%	20,612
26-09-02	US$3.430	+2.39%	35,186
26-09-01	US$3.350	-5.37%	60,232
26-08-31	US$3.540	-15.31%	261,260

Delayed Quote Nasdaq

More quotes

Quarterly revenue - Rate of surprise

Company calendar

1 day	+0.61%
1 week	-21.53%
Current month	-7.34%
1 month	-43.20%
3 months	-81.94%
6 months	-89.58%
Current year	-95.71%

1 week	2.88	3.65
1 month	2.88	11.2
Current year	2.88	81.75
1 year	2.88	137.96
3 years	2.88	1,463.25
5 years	2.88	1,463.25
10 years	2.88	1,463.25

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/31/26	Andrew Cutler	Free	Director	472,222	0.9792%
6/29/26	Tomas Philipson	Free	Director	536,428	1.1124%
6/2/26	Holger Weis	Free	Director	100,000	0.2756%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JUPITER NEUROSCIENCES, INC.	+0.61%	-21.53%	-96.44%	-	2.53M
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+43.23%	+88.96%	67.98B
ARGENX SE	-2.06%	-0.18%	+39.67%	+86.44%	64.94B
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+378.92%	27.58B
BIONTECH SE	+0.86%	+1.65%	-7.74%	-14.95%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+33.13%	+12.54%	25.74B
GENMAB A/S	-1.46%	+0.42%	+23.61%	-18.61%	20.09B
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+216.20%	+368.10%	17.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-6.60%	+531.89%	14.92B
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+164.98%	14.62B
Average	-1.18%	-1.92%	+28.79%	+177.58%	27.91B
Weighted average by Cap.	-1.52%	+0.18%	+38.37%	+137.35%

	2024	2025
Net sales	-	21.8K 18.77K 17.65K 16.13K 30.15K 2.06M 30.25K 208K 80.85K 1.05M 81.84K 80.05K 3.4M
Net income	-2.44M -2.1M -1.98M -1.81M -3.38M -230M -3.39M -23.32M -9.05M -118M -9.16M -8.96M -381M	-8.64M -7.44M -7M -6.4M -11.96M -817M -12M -82.64M -32.07M -418M -32.46M -31.75M -1.35B
Net Debt	-3.55M -3.06M -2.88M -2.63M -4.91M -336M -4.93M -33.95M -13.18M -172M -13.34M -13.04M -555M	1.53M 1.32M 1.24M 1.13M 2.12M 145M 2.12M 14.63M 5.68M 74.05M 5.74M 5.62M 239M

Jupiter Neurosciences, Inc. Stock

Stocks

JUNS

US48208B3024

Biotechnology & Medical Research

Valuation : Jupiter Neurosciences, Inc.

Chart: Jupiter Neurosciences, Inc.

Latest news : Jupiter Neurosciences, Inc.

Analysts' recommendations : Jupiter Neurosciences, Inc.

Press Releases : Jupiter Neurosciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Jupiter Neurosciences, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise